New data provided to CNBC from eVestment shows the most popular stocks held by institutional funds.» Read More
Investors are eager to hear results from Amylin and Biogen, Thursday. It seems the future of both firms could lie in the hands of Fast Money friend Carl Icahn!
Eric writes, “I know Karen likes some of the names in biotech. Would she be a buyer of Biogen ahead of earnings this week?”
After a five-week rally, stocks face one of their toughest challenges yet - a very nasty earnings season.
Once again, activist investor Carl Icahn turns to Fast Money to set the record straight on all the rumors surrounding his wheeling and dealing.
Following are the day’s biggest winners and losers. Find out why shares of Biogen and Brinker International popped while Exxon Mobil and MGM Mirage dropped.
Stock and options traders are piling into Biogen Idec on speculation that the drug maker could be a takeover target. About 75,000 options contracts traded on the name, more than 10 times the average over the last 20 session...
Which companies are looking like top takeover targets, right now? Jon Najarian has spotted hot options action in three stocks!
The Pit Boss is seeing explosive options action in a drug stock. Find out which one!
Cougar Biotech has a drug in its pipeline that could offer big help to patients with this disease.
The IBB biotech ETF is drawing strong options activity Thursday, as news ranging from mergers to government regulation continues to rock the sector.
Even though nearly every analyst this morning is saying Thursday's bloodbath was an overreaction, investors are continuing to sell biopharma stocks in the early going Friday.
Rob Morgan of Clermont Wealth Strategies got some encouragement from President Obama's remarks about stimulus and recovery, but not enough to make him bullish on financials. That's not to say he's completely down on stocks.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
The Dow rallied for a second day on Friday on hopes Washington's stimulus package and a bank rescue plan will bolster the ailing economy.
Stocks will take their cue from the jobs report Friday, but it's the news from Washington that could once more drive the market.
In this Web Extra the traders talk earnings from Biogen, Toyota, Corning and more. What's the trade?
The Dow and S&P 500 fell on Monday as uncertainty about the Obama administration's plan to stem bank losses dragged down financial shares.
Call options are heating up in Amgen, which is up slightly Monday in a sluggish market. As AMGN trades at about $55.20 the Febuary 57.5 and 60 calls are drawing a few nibbles, but most of today's action involves the Febuary 65 calls. What's it mean?
Diabetes drugmaker Amylin Pharmaceuticals is headquartered in San Diego. Like a lot of companies, though, it's incorporated in Delaware. But, if a couple of major shareholders get their way, AMLN could reincorporate in an unlikely state.
Speculation is swirling that Elan could be on the brink of merger after the firm hired Citigroup to conduct a strategic review. Find out what the Fast Money traders are hearing.